DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322 Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use. 0

https://www.zacks.com/stock/news/2226983/alnylam-alny-reports-q4-earnings-what-key-metrics-have-to-say?cid=CS-ZC-FT-fundamental_analysis|nfm-2226983 Feb 15, 2024 - While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values. 0

https://www.zacks.com/stock/news/2226283/drug-biotech-stock-q4-earnings-due-on-feb-15-alny-bpmc-more?cid=CS-ZC-FT-analyst_blog|earnings_preview_-_esp-2226283 Feb 14, 2024 - Let's look at five biotech/drug companies, ALNY, BPMC, AGIO, CORT and RARE, slated to release quarterly results on Feb 15. 0

https://www.zacks.com/stock/news/2224670/gear-up-for-alnylam-alny-q4-earnings-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224670 Feb 12, 2024 - Beyond analysts' top -and-bottom-line estimates for Alnylam (ALNY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023. 0

https://www.zacks.com/stock/news/2223431/alnylam-pharmaceuticals-alny-expected-to-beat-earnings-estimates-can-the-stock-move-higher?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2223431 Feb 08, 2024 - Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. 0

https://www.zacks.com/stock/news/2193043/apellis-apls-rides-on-syfovre-to-fuel-growth-amid-rivalry?cid=CS-ZC-FT-analyst_blog|zer_report_update-2193043 Dec 04, 2023 - Apellis' (APLS) marketed products, Syfovre and Empaveli, continue to remain the growth drivers since launch. However, stiff competition in the target markets remains a woe. 0